Download MendeleyOptimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.
Brnardic, E.J., Garbaccio, R.M., Fraley, M.E., Tasber, E.S., Steen, J.T., Arrington, K.L., Dudkin, V.Y., Hartman, G.D., Stirdivant, S.M., Drakas, B.A., Rickert, K., Walsh, E.S., Hamilton, K., Buser, C.A., Hardwick, J., Tao, W., Beck, S.C., Mao, X., Lobell, R.B., Sepp-Lorenzino, L., Yan, Y., Ikuta, M., Munshi, S.K., Kuo, L.C., Kreatsoulas, C.(2007) Bioorg Med Chem Lett 17: 5989-5994
- PubMed: 17804227
- DOI: https://doi.org/10.1016/j.bmcl.2007.07.051
- Primary Citation of Related Structures:
2QHM, 2QHN - PubMed Abstract:
The development of 2,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-ones as inhibitors of Chk1 kinase is described. Introduction of a fused ring at the C7/C8 positions of the pyrazoloquinolinone provided an increase in potency while guidance from overlapping inhibitor bound Chk1 X-ray crystal structures contributed to the discovery of a potent and solubilizing propyl amine moiety in compound 52 (Chk1 IC(50)=3.1 nM).
Organizational Affiliation:
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. edward_brnardic@merck.com
